TLDR Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
Baricitinib, a JAK1/2 inhibitor initially approved for rheumatoid arthritis, has shown efficacy in treating various inflammatory and autoimmune diseases, including COVID-19, systemic lupus erythematosus, psoriasis, atopic dermatitis, and alopecia areata. Clinical trials have demonstrated significant improvements in disease activity and symptoms across these conditions, with notable hair regrowth in alopecia areata patients. However, its use is associated with adverse effects such as infections, liver enzyme dysregulation, and potential malignancies, necessitating careful monitoring and further research to fully understand its safety profile and optimize treatment regimens.
25 citations,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
184 citations,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
9 citations,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
3 citations,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
70 citations,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
